Report Summary
Eternity Insights can provide a deep dive research report highlighting the market and competitive in-telligence across the key segments of the market. The report also considers the impact of COVID-19 on the global Female Contraceptive market. The report considers 2018-2020 historic period, 2021 as base year, and 2022-2028 as forecast period. The report includes quantitative analysis of the market supported by the mar-ket drivers, challenges, and trends to accurately map the market scenario and competition.
Female Contraceptive market report is based on robust research methodology designed using blend of research ap-proaches developed using secondary/desk research and validated through the primary research and expert insights. Eternity Insights also uses paid data bases such as FACIVA, Hoovers, and other bench-marking and forecasting tools to provide accurate statistical analysis of supply and demand trends.
To learn more about this report
Key Research Highlights: Market Drivers
The Female Contraceptive market is estimated to expand at a considerable growth rate during the forecast period ow-ing to increasing prevalence of venous diseases and increasing new product approvals to cater this demand. Rise in the awareness about the diseases, increasing importance of early diagnosis, and growing spending on chronic diseases are poised to boost the market growth. Moreover, the key players in the market are investing in research and development of technologically advanced products leading to increased utilization of the Female Contraceptive products across developed and developing countries of the world.
Key Research Highlights: Market Restrains
Limited awareness about the diseases, high cost of products, low economical condition, and lack of favorable insurance systems restricts the adoption of Female Contraceptive products across developing regions of the globe. However, launch of new products with low cost and increasing efforts for market penetration in these regions can offer lucrative growth opportunities for the players in the Female Contraceptive market.
To learn more about this report
Key Research Highlights: Trends
Increasing research and development spending on Female Contraceptive development has been the leading industry trend of Female Contraceptive market
The leading players in the market are focused on developing products which are cost effective and high quality to tap the huge unaddressed opportunities in the developing regions. This can be wit-nessed from the increasing spending on research and development and growing number of new product approvals.
Global Female Contraceptive Market Size, 2018-2028 (USD MILLION)
To learn more about this report
Market Segmentation
| Report Attributes |
Details |
| The market size value in 2021 |
USD XX.XX Million |
| CAGR (2021 - 2028) |
XX.XX % |
| The Revenue forecast in 2028 |
USD XX.XX Million |
| Base year for estimation |
2021 |
| Historical data |
2018-2019 |
| Forecast period |
2022-2028 |
| Quantitative units |
- Revenue in USD Million
- CAGR from 2021 to 2028
|
| Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments covered |
By Type Outlook, Application Outlook, Regional Outlook |
| By Type Outlook |
Female Contraceptive Devices, Female Contraceptive Drugs, Other |
| By Application Outlook |
Online Stores, Retail Outlets, Other |
| Regional scope |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Country scope |
U.S., Canada, U.K., Germany, France, BENELUX, China, India, Japan, South Korea, Brazil, Saudi Arabia, UAE, Turkey |
| Key companies profiled |
Merck, Pfizer, Allergan, Bayer, Okamoto Industries, Reckitt Benckiser, Lupin Pharmaceuticals, Foundation Consumer Healthcare, Teva Pharmaceuticals, Ansell, Ferring Pharmaceuticals, Fuji Latex, Janssen Pharmaceuticals |
| Customization Available |
Yes, the report can be tailored to meet your specific requirements. |
Key Market Players
- Merck
- Pfizer
- Allergan
- Bayer
- Okamoto Industries
- Reckitt Benckiser
- Lupin Pharmaceuticals
- Foundation Consumer Healthcare
- Teva Pharmaceuticals
- Ansell
- Ferring Pharmaceuticals
- Fuji Latex
- Janssen Pharmaceuticals
Female Contraceptive Market, By Type
- Female Contraceptive Devices
- Female Contraceptive Drugs
- Other
Female Contraceptive Market, By Application
- Online Stores
- Retail Outlets
- Other
Key Benefits To The Stake Holders
- Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors
- Provision of market value (USD Billion) and volume (Tons) data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry with respect to recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Table Of Contents
Table of Contents
1 Study Coverage
1.1 Female Contraceptive Product
1.2 Market Segments
1.3 Key Manufacturers Covered
1.4 Market by Type
1.4.1 Global Female Contraceptive Market Size Growth Rate by Product
1.4.2 Female Contraceptive Devices
1.4.3 Female Contraceptive Drugs
1.5 Market by End User
1.5.1 Global Female Contraceptive Market Size Growth Rate by End User
1.5.2 Online Stores
1.5.3 Retail Outlets
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Female Contraceptive Market Size
2.1.1 Global Female Contraceptive Revenue 2017-2027
2.1.2 Global Female Contraceptive Sales 2017-2027
2.2 Female Contraceptive Growth Rate by Regions
2.2.1 Global Female Contraceptive Sales by Regions
2.2.2 Global Female Contraceptive Revenue by Regions
3 Breakdown Data by Manufacturers
3.1 Female Contraceptive Sales by Manufacturers
3.1.1 Female Contraceptive Sales by Manufacturers
3.1.2 Female Contraceptive Sales Market Share by Manufacturers
3.1.3 Global Female Contraceptive Market Concentration Ratio (CR5 and HHI)
3.2 Female Contraceptive Revenue by Manufacturers
3.2.1 Female Contraceptive Revenue by Manufacturers (2017-2020)
3.2.2 Female Contraceptive Revenue Share by Manufacturers (2017-2020)
3.3 Female Contraceptive Price by Manufacturers
3.4 Female Contraceptive Manufacturing Base Distribution, Product Types
3.4.1 Female Contraceptive Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Female Contraceptive Product Type
3.4.3 Date of International Manufacturers Enter into Female Contraceptive Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
4.1 Global Female Contraceptive Sales by Product
4.2 Global Female Contraceptive Revenue by Product
4.3 Female Contraceptive Price by Product
5 Breakdown Data by End User
5.1 Overview
5.2 Global Female Contraceptive Breakdown Data by End User
6 North America
6.1 North America Female Contraceptive by Countries
6.1.1 North America Female Contraceptive Sales by Countries
6.1.2 North America Female Contraceptive Revenue by Countries
6.1.3 United States
6.1.4 Canada
6.1.5 Mexico
6.2 North America Female Contraceptive by Product
6.3 North America Female Contraceptive by End User
7 Europe
7.1 Europe Female Contraceptive by Countries
7.1.1 Europe Female Contraceptive Sales by Countries
7.1.2 Europe Female Contraceptive Revenue by Countries
7.1.3 Germany
7.1.4 France
7.1.5 UK
7.1.6 Italy
7.1.7 Russia
7.2 Europe Female Contraceptive by Product
7.3 Europe Female Contraceptive by End User
8 Asia Pacific
8.1 Asia Pacific Female Contraceptive by Countries
8.1.1 Asia Pacific Female Contraceptive Sales by Countries
8.1.2 Asia Pacific Female Contraceptive Revenue by Countries
8.1.3 China
8.1.4 Japan
8.1.5 Korea
8.1.6 India
8.1.7 Australia
8.1.8 Indonesia
8.1.9 Malaysia
8.1.10 Philippines
8.1.11 Thailand
8.1.12 Vietnam
8.1.13 Singapore
8.2 Asia Pacific Female Contraceptive by Product
8.3 Asia Pacific Female Contraceptive by End User
9 Central & South America
9.1 Central & South America Female Contraceptive by Countries
9.1.1 Central & South America Female Contraceptive Sales by Countries
9.1.2 Central & South America Female Contraceptive Revenue by Countries
9.1.3 Brazil
9.2 Central & South America Female Contraceptive by Product
9.3 Central & South America Female Contraceptive by End User
10 Middle East and Africa
10.1 Middle East and Africa Female Contraceptive by Countries
10.1.1 Middle East and Africa Female Contraceptive Sales by Countries
10.1.2 Middle East and Africa Female Contraceptive Revenue by Countries
10.1.3 GCC Countries
10.1.4 Turkey
10.1.5 Egypt
10.1.6 South Africa
10.2 Middle East and Africa Female Contraceptive by Product
10.3 Middle East and Africa Female Contraceptive by End User
11 Company Profiles
11.1 Merck
11.1.1 Merck Company Details
11.1.2 Company Business Overview
11.1.3 Merck Female Contraceptive Sales, Revenue and Gross Margin (2017-2020)
11.1.4 Merck Female Contraceptive Products Offered
11.1.5 Merck Recent Development
11.2 Pfizer
11.2.1 Pfizer Company Details
11.2.2 Company Business Overview
11.2.3 Pfizer Female Contraceptive Sales, Revenue and Gross Margin (2017-2020)
11.2.4 Pfizer Female Contraceptive Products Offered
11.2.5 Pfizer Recent Development
11.3 Allergan
11.3.1 Allergan Company Details
11.3.2 Company Business Overview
11.3.3 Allergan Female Contraceptive Sales, Revenue and Gross Margin (2017-2020)
11.3.4 Allergan Female Contraceptive Products Offered
11.3.5 Allergan Recent Development
11.4 Bayer
11.4.1 Bayer Company Details
11.4.2 Company Business Overview
11.4.3 Bayer Female Contraceptive Sales, Revenue and Gross Margin (2017-2020)
11.4.4 Bayer Female Contraceptive Products Offered
11.4.5 Bayer Recent Development
11.5 Okamoto Industries
11.5.1 Okamoto Industries Company Details
11.5.2 Company Business Overview
11.5.3 Okamoto Industries Female Contraceptive Sales, Revenue and Gross Margin (2017-2020)
11.5.4 Okamoto Industries Female Contraceptive Products Offered
11.5.5 Okamoto Industries Recent Development
11.6 Reckitt Benckiser
11.6.1 Reckitt Benckiser Company Details
11.6.2 Company Business Overview
11.6.3 Reckitt Benckiser Female Contraceptive Sales, Revenue and Gross Margin (2017-2020)
11.6.4 Reckitt Benckiser Female Contraceptive Products Offered
11.6.5 Reckitt Benckiser Recent Development
11.7 Lupin Pharmaceuticals
11.7.1 Lupin Pharmaceuticals Company Details
11.7.2 Company Business Overview
11.7.3 Lupin Pharmaceuticals Female Contraceptive Sales, Revenue and Gross Margin (2017-2020)
11.7.4 Lupin Pharmaceuticals Female Contraceptive Products Offered
11.7.5 Lupin Pharmaceuticals Recent Development
11.8 Foundation Consumer Healthcare
11.8.1 Foundation Consumer Healthcare Company Details
11.8.2 Company Business Overview
11.8.3 Foundation Consumer Healthcare Female Contraceptive Sales, Revenue and Gross Margin (2017-2020)
11.8.4 Foundation Consumer Healthcare Female Contraceptive Products Offered
11.8.5 Foundation Consumer Healthcare Recent Development
11.9 Teva Pharmaceuticals
11.9.1 Teva Pharmaceuticals Company Details
11.9.2 Company Business Overview
11.9.3 Teva Pharmaceuticals Female Contraceptive Sales, Revenue and Gross Margin (2017-2020)
11.9.4 Teva Pharmaceuticals Female Contraceptive Products Offered
11.9.5 Teva Pharmaceuticals Recent Development
11.10 Ansell
11.10.1 Ansell Company Details
11.10.2 Company Business Overview
11.10.3 Ansell Female Contraceptive Sales, Revenue and Gross Margin (2017-2020)
11.10.4 Ansell Female Contraceptive Products Offered
11.10.5 Ansell Recent Development
11.11 Ferring Pharmaceuticals
11.12 Fuji Latex
11.13 Janssen Pharmaceuticals
12 Future Forecast
12.1 Female Contraceptive Market Forecast by Regions
12.1.1 Global Female Contraceptive Sales Forecast by Regions 2021-2027
12.1.2 Global Female Contraceptive Revenue Forecast by Regions 2021-2027
12.2 Female Contraceptive Market Forecast by Product
12.2.1 Global Female Contraceptive Sales Forecast by Product 2021-2027
12.2.2 Global Female Contraceptive Revenue Forecast by Product 2021-2027
12.3 Female Contraceptive Market Forecast by End User
12.4 North America Female Contraceptive Forecast
12.5 Europe Female Contraceptive Forecast
12.6 Asia Pacific Female Contraceptive Forecast
12.7 Central & South America Female Contraceptive Forecast
12.8 Middle East and Africa Female Contraceptive Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Female Contraceptive Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
